Newswise — May 16, 2017 – Increased investment in "pharmacovigilance surveillance"—systems to proactively monitor safety problems with new medications—has the potential to avoid harmful drug effects while lowering healthcare costs, according to a study in the June issue of Medical Care. The journal is published by Wolters Kluwer.
Three recent cases in which serious safety issues led to medication withdrawals illustrate the potential return on investment of building a more effective pharmacovigilance surveillance system, according to the report by Krista F. Huybrechts, PhD, of Brigham and Women's Hospital, Boston, and colleagues. They write, "Our analyses demonstrate a pivotal and economically justifiable role for active pharmacovigilance in protecting the health of the public."
Detecting 'Early Signals' Could Have Avoided Drug Adverse Events
The researchers analyzed three important instances of major adverse drug events that led to medications being taken off the market. In each case, early signs of medication safety hazards could have been picked up from clinical trials and/or spontaneous reports. However, these problems went unrecognized, with continued patient exposure leading to avoidable complications and costs.
The highest-profile example was the "COX2 inhibitor" rofecoxib (marketed as Vioxx), widely used for arthritis treatment. In more than five years on the market, approximately 105 million rofecoxib prescriptions were filled by US patients. Over time, it became clear that this medication was associated with a substantially increased risk of acute myocardial infarction (heart attack).
But this adverse effect could have been detected as early as one year after rofecoxib appeared on the market, based on analyses of actual healthcare utilization data available at the time. Early signal detection based on active pharmacovigilance surveillance could have averted 27,500 myocardial infarctions, Dr. Huybrechts and colleagues estimate.
In the other two cases, active surveillance might have avoided 190 cases of a rare but serious complication called rhabdomyolysis in patients taking the cholesterol-lowering drug cerivastatin (Baycol); and 264 cases of liver failure attributable to the diabetes drug troglitazone (Rezulin). The authors note that there were questions about the true benefits of all three drugs, and that other treatment options were available.
Earlier recognition of these safety issues could have resulted in savings in direct medical costs of $773 to $884 million for rofecoxib, $3 to $10 million for cerivastatin, and $38 to $63 million for troglitazone. Those figures don't consider indirect financial costs such as missed work time—not to mention the human costs of experiencing a potentially serious complication.
The researchers believe their findings illustrate the potential return on investment in pharmacovigilance surveillance programs—a function that is historically "overburdened and under-funded." In the United States, investment in pharmacovigilance is estimated at about $42.5 million per year.
While the frequency of new drug safety concerns is unpredictable, "It is clear that major adverse drug events are not rare," Dr. Dr. Huybrechts and coauthors write. "Investment in active drug surveillance offers protection against the occurrence of such events, which are bound to recur."
Article: “The Potential Return on Public Investment in Detecting Adverse Drug Effects” (doi: 10.1097/MLR.0000000000000717)
About Medical Care
Rated as one of the top ten journals in health care administration, Medical Care is devoted to all aspects of the administration and delivery of health care. This scholarly journal publishes original, peer-reviewed papers documenting the most current developments in the rapidly changing field of health care. Medical Care provides timely reports on the findings of original investigations into issues related to the research, planning, organization, financing, provision, and evaluation of health services. In addition, numerous special supplementary issues that focus on specialized topics are produced with each volume. Medical Care is the official journal of the Medical Care Section of the American Public Health Association
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
MEDIA CONTACTRegister for reporter access to contact details